Actionable news
0
All posts from Actionable news
Actionable news in ADHD: Alcobra Ltd.,

Novogen Licenses Phase II-ready Molecule from Genentech for Development in Glioblastoma for $5M Upfront , Plus Milestones

Novogen Ltd (NASDAQ: NVGN) today announced that it has entered into a worldwide licensing agreement with Genentech, a member of the Roche Group (OTC: RHHBY), to develop and commercialise GDC-0084, a small molecule inhibitor of the phosphoinositide-3-kinase (PI3K) pathway.

The lead indication for GDC-0084 is glioblastoma multiforme (GBM), which is the most aggressive form of brain cancer, accounting for approximately 15% of primary brain tumours. Median overall survival is considered to be approximately 12 – 15 months from the time of diagnosis.

Therapies targeting the PI3K pathway have been under development by a number of pharmaceutical and biotechnology companies for several years, in various types of cancer. GDC-0084 is distinguished from most molecules in the class by its ability to cross the blood-brain barrier, potentially making it suitable for cancers of the central nervous system.

Genentech has completed a phase I study of...


More